These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 9744340)

  • 1. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
    Muratet JP; Daver A; Minier JF; Larra F
    J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
    Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
    J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
    Dam HQ; Kim SM; Lin HC; Intenzo CM
    Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
    Silberstein EB
    J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
    Gerard SK; Dam HQ
    Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
    [No Abstract]   [Full Text] [Related]  

  • 6. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the efficacy of iodine-131 for thyroid ablation.
    Comtois R; Thériault C; Del Vecchio P
    J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
    Bajén MT; Mañé S; Muñoz A; García JR
    J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK; Murby B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
    Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
    Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
    Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
    J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
    Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
    Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer.
    Samuel AM; Rajashekharrao B; Shah DH
    J Nucl Med; 1998 Sep; 39(9):1531-6. PubMed ID: 9744337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiated thyroid carcinoma: Incremental diagnostic value of
    Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
    Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stunning effects after a diagnostic dose of iodine-131.
    Kao CH; Yen TC
    Nuklearmedizin; 1998 Jan; 37(1):30-2. PubMed ID: 9467167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals.
    Morris LF; Waxman AD; Braunstein GD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.